Qingyu Luo

Harvard Medical School

H指数:19

被引数:914

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy

活细胞Pick-Seq (LiP-Seq)：CART19疗法后检测超罕见套细胞淋巴瘤持续性细胞

Blood Advances

IF7.1

2026-03-230

OAAI

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer

靶向从头嘧啶合成使对铜介导的ATR失活敏感的PARP抑制剂耐药性卵巢癌易感。

Nature Communications

IF15.7

2026-02-250

OAAI

Targetable leukaemia dependency on noncanonical PI3Kγ signalling

靶向白血病对非规范PI3Kγ 信号的依赖性

Nature

IF48.5

2024-05-080

PRE

OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition

OTUB2沉默通过线粒体代谢重编程促进卵巢癌，并且可以通过CA9抑制合成靶向

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2024-05-034

OAAI

RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-κB activation and ovarian cancer progression

ONCOGENE

IF7.3

2023-12-145

PRE

m6A demethylase FTO stabilizes LINK-A to exert oncogenic roles via MCM3-mediated cell-cycle progression and HIF-1a activation

CELL REPORTS

IF6.9

2023-10-018

HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity

MOLECULAR THERAPY

IF12

2023-02-0117

OAAI

OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased

CELL REPORTS

IF6.9

2022-10-0115

DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma

CANCER RESEARCH

IF16.6

2022-06-2215

OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation

OTUD1通过促进AIF核易位和MCL1降解来激活不依赖半胱天冬酶和依赖半胱天冬酶的细胞凋亡

ADVANCED SCIENCE

IF14.1

2021-02-0849

ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2 (vol 427, pg 9, 2018)

CANCER LETTERS

IF10.1

2021-02-010

PREAI

Remodeling of the ARID1A tumor suppressor

CANCER LETTERS

IF10.1

2020-10-019

PREAI

ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression (vol 80, pg 406, 2020)

CANCER RESEARCH

IF16.6

2020-10-010

PRE

Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options

CELL DEATH & DISEASE

IF9.6

2020-07-2258

OAAI

Downregulation of the GLP-1/CREB/adiponectin pathway is partially responsible for diabetes -induced dysregulated vascular tone and VSMC dysfunction

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2020-07-0118

OAAI

ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression

ARID1A高甲基化破坏转录稳态促进鳞状细胞癌进展

CANCER RESEARCH

IF16.6

2020-02-0322

OAAI

TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma

CELL REPORTS

IF6.9

2020-01-0141

OAAI

ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness

CELL DEATH AND DIFFERENTIATION

IF15.4

2019-12-1235

OAAI

JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1

CELL DEATH AND DIFFERENTIATION

IF15.4

2019-05-0150

OAAI

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer

MGMT激活的DUB3稳定MCL1并驱动卵巢癌的化学抗性

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2019-02-0467

OAAI

Qingyu Luo

个人简介

教育背景

工作经历

荣誉奖项

研究方向